Global Dermatology Drugs Market to 2024 – IL Signaling Inhibitors to Overtake TNF-a Inhibitors as Leading Commercial Drug Class with Dupixent and Cosentyx among Key Performers

Dermatological conditions, diseases of the skin, hair and nails, are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established products, which are largely genericized. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline. This report covers all dermatological disorders, but there is a particular focus on three key diseases, atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the largest pipelines within the therapy area as well as large prevalent populations. The market size for dermatology therapeutics was valued at $35.9 billion in 2017 and it is expected to grow at a compound annual growth rate (CAGR) of 7.18% to $58.2 billion in 2024.

Scope

– How is the dermatology landscape expected to change?

– Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?

– Overall, there are 936 products in the dermatology pipeline, how does the composition of the pipeline compare with that of the existing market?

– Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?

– The market size for dermatology therapeutics is expected to grow, from $35.9 billion in 2017 to $58.2 billion in 2024, at a CAGR of 7.18%. Which products will contribute to market growth most, and which will achieve blockbuster status?

– What types of companies are involved in the dermatology therapy area?

– Will the current market leaders retain their dominance over the forecast period?

– How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the three key indications.

- Visualize the composition of the dermatology market, highlighting the key commercial assets and players.

- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the dermatology drugs market.

- Identify trends and developments in the dermatology pipeline, and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.

- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various dermatological conditions.

- Identify which drug classes will see particularly strong market growth over the forecast period.

- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion.

- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Therapy Area Introduction

2.2 Symptoms

2.3 Diagnosis, Scales and Grading

2.3.1 Atopic Dermatitis

2.3.2 Acne Vulgaris

2.3.3 Psoriasis

2.4 Etiology

2.5 Pathophysiology

2.5.1 Atopic Dermatitis

2.5.2 Acne Vulgaris

2.5.3 Psoriasis

2.6 Epidemiology

2.6.1 Atopic Dermatitis

2.6.2 Acne Vulgaris

2.6.3 Psoriasis

2.7 Comorbidities and Complications

2.8 Treatment

2.8.1 Topical Corticosteroids

2.8.2 Calcineurin Inhibitors

2.8.3 Retinoids

2.8.4 Systemic Immunosuppressive Agents

2.8.5 Biologics

2.8.6 Antihistamines

2.8.7 Hormonal Therapy

2.8.8 Moisturizers

3 Key Marketed Products

3.1 Overview

3.2 Humira (adalimumab) - AbbVie

3.3 Enbrel (etanercept) - Amgen

3.4 Remicade (infliximab) – Johnson & Johnson

3.5 Stelara (ustekinumab) – Johnson & Johnson

3.6 Cosentyx (secukinumab) - Novartis

3.7 Taltz (ixekizumab) – Eli Lilly

3.8 Dupixent (dupilumab) - Sanofi

3.9 Eucrisa (crisaborole) - Pfizer

3.10 Neoral (cyclosporine) – Novartis

3.11 Protopic (Tacrolimus) – Leo Pharma

3.12 Elidel (pimecrolimus) – Bausch Health

3.13 Differin (adapalene) – Galderma

3.14 Elocon (mometasone furoate) – Merck & Co.

3.15 Metolate (methotrexate)

3.16 Clobex (clobetasol propionate) – Galderma

3.17 Aczone (dapsone) – Almirall

3.18 Retin-A (tretinoin) – Bausch Health

3.19 Episalvan (birch bark extract) – Amryt Pharma

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Molecular Targets in the Pipeline

4.4 Clinical Trials

4.4.1 Clinical Trial Failure Rates

4.4.2 Clinical Trial Duration

4.4.3 Clinical Trial Size

4.4.4 Cumulative Clinical Program Size

4.5 Assessment of Key Late-Stage Pipeline Products

4.5.1 Risankizumab – AbbVie

4.5.2 MOR106 – MorphoSys/Galapagos/Novartis

4.5.3 ANB-019 – AnaptysBio

4.5.4 Lebrikizumab – Dermira

4.5.5 FMX-101 (minocycline) – Foamix

5 Multi-scenario Market Forecast to 2024

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Molecular Target Class

5.3.1 TNF-a inhibitors

5.3.2 IL-17 inhibitors

5.3.3 IL-23 inhibitors

5.3.4 Other IL inhibitors (ILs 1, 4, 12, 13, 33 and 36 and receptors)

5.3.5 PDE4 inhibitors

5.3.6 Glucocorticoids

5.3.7 JAK inhibitors

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company

6.1.1 AbbVie – Company to maintain market leadership despite declining market share

6.1.2 Novartis – Success of Cosentyx to increase company’s market share

6.1.3 Johnson & Johnson – Stelara and Tremfya to offset revenue losses from Remicade

6.1.4 Sanofi – Company to become one of the leading players due to Dupixent’s success

6.1.5 Pfizer – Approval of Eucrisa to drive growth in the dermatology therapy area

6.1.6 Eli Lilly – New products Taltz and Olumiant to drive market growth

6.2 Company Landscape

6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.1.1 Deals by Region, Deal Value and Year

7.1.2 Deals by Indication and Deal Value

7.1.3 Deals by Stage of Development and Deal Value

7.1.4 Deals by Molecule Type, Molecular Target and Deal Value

7.1.5 Figures of Licensing Deals with Disclosed Values

7.2 Co-development Deals

7.2.1 Deals by Region, Deal Value and Year

7.2.2 Deals by Indication and Deal Value

7.2.3 Deals by Stage of Development and Deal Value

7.2.4 Deals by Molecule Type, Molecular Target and Deal Value

7.2.5 Figures of Co-development Deals with Disclosed Values

8 Appendix

8.1 References

8.2 Figures of All Clinical Stage Pipeline Products

8.3 Abbreviations

8.4 Disease List

8.5 Methodology

8.5.1 Coverage

8.5.2 Secondary Research

8.5.3 Market Size and Revenue Forecasts

8.5.4 Pipeline Analysis

8.5.5 Competitive Landscape

8.6 Contact Us

8.7 Disclaimer

List of Tables

List of Tables

Table 1: Dermatology Drugs Market , Global, Classification of Atopic Dermatitis Severity and Impact on Quality of Life, 2018 14

Table 2: Dermatology Drugs Market , Global, Comparison of Acne Grading Scales Used in Europe and the US, 2018 15

Table 3: Dermatology Drugs Market, Global, Classification of Psoriasis Severity, 2018 16

Table 4: Dermatology Drugs Market, 7MM, Epidemiology of Dermatological Disorders, 2018 21

Table 5: Dermatology Drugs Market, Global, Approved Dermatology Indications for Humira, 2018 31

Table 6: Dermatology Drugs Market, Global, Approved Dermatology Indications for Enbrel, 2018 33

Table 7: Dermatology Drugs Market, Global, Approved Dermatology Indications for Remicade, 2018 35

Table 8: Dermatology Drugs Market, Global, Approved Dermatology Indications for Stelara, 2018 37

Table 9: Dermatology Drugs Market, Global, Approved Dermatology Indications for Cosentyx, 2018 38

Table 10: Dermatology Drugs Market, Global, Approved Dermatology Indications for Taltz, 2018 40

Table 11: Dermatology Drugs Market, Global, Approved Dermatology Indications for Dupixent, 2018 42

Table 12: Dermatology Drugs Market, Global, Approved Dermatology Indications for Eucrisa, 2018 43

Table 13: Dermatology Drugs Market, Global, Approved Dermatology Indications for Neoral, 2018 44

Table 14: Dermatology Drugs Market, Global, Approved Dermatology Indications for Protopic, 2018 46

Table 15: Dermatology Drugs Market, Global, Approved Dermatology Indications for Elidel, 2018 47

Table 16: Dermatology Drugs Market, Global, Approved Dermatology Indications for Differin, 2018 49

Table 17: Dermatology Drugs Market, Global, Approved Dermatology Indications for Elocon, 2018 50

Table 18: Dermatology Drugs Market, Global, Approved Dermatology Indications for Clobex, 2018 52

Table 19: Dermatology Drugs Market, Global, Approved Dermatology Indications for Aczone, 2018 53

Table 20: Dermatology Drugs Market, Global, Approved Dermatology Indications for Retin-A, 2018 55

Table 21: Dermatology Drugs Market, Global, Approved Dermatology Indications for Episalvan, 2018 56

Table 22: Dermatology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017–2024 87

Table 23: Dermatology Drugs Market, Global, Usage of Generics Across Key Indications, 2018 89

Table 24: Dermatology Drugs Market, Global, Forecast Revenue by Company, 2017–2024 101

List of Figures

List of Figures

Figure 1: Dermatology Drugs Market, 7MM, Epidemiology Patterns for Atopic Dermatitis, 2017–2024 21

Figure 2: Dermatology Drugs Market, 7MM, Epidemiology Patterns for Acne Vulgaris, 2017–2024 22

Figure 3: Dermatology Drugs Market, 7MM, Epidemiology Patterns for Psoriasis, 2017–2024 23

Figure 4: Dermatology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 30

Figure 5: Dermatology Drugs Market, Global, Annual Revenue for Humira ($bn), 2006–2024 32

Figure 6: Dermatology Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006–2024 34

Figure 7: Dermatology Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006–2024 36

Figure 8: Dermatology Drugs Market, Global, Annual Revenue for Stelara ($bn), 2010–2024 38

Figure 9: Dermatology Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015–2024 40

Figure 10: Dermatology Drugs Market, Global, Annual Revenue for Taltz ($bn), 2016–2024 41

Figure 11: Dermatology Drugs Market, Global, Annual Revenue for Dupixent ($bn), 2017–2024 43

Figure 12: Dermatology Drugs Market, Global, Annual Revenue for Eucrisa ($bn), 2016–2024 44

Figure 13: Dermatology Drugs Market, Global, Annual Revenue for Neoral ($m), 2006–2024 46

Figure 14: Dermatology Drugs Market, Global, Annual Revenue for Protopic ($m), 2006–2015 47

Figure 15: Dermatology Drugs Market, Global, Annual Revenue for Elidel ($m), 2006–2024 48

Figure 16: Dermatology Drugs Market, Global, Annual Revenue for Differin ($m), 2008–2015 50

Figure 17: Dermatology Drugs Market, Global, Annual Revenue for Elocon ($m), 2006–2024 51

Figure 18: Dermatology Drugs Market, Global, Annual Revenue for Metolate ($m), 2007–2013 52

Figure 19: Dermatology Drugs Market, Global, Annual Revenue for Aczone ($m), 2015–2024 54

Figure 20: Dermatology Drugs Market, Global, Annual Revenue for Retin-A ($m), 2014–2024 56

Figure 21: Dermatology Drugs Market, Global, Annual Revenue for Episalvan ($m), 2020–2024 58

Figure 22: Dermatology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 59

Figure 23: Dermatology Drugs Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2018 61

Figure 24: Dermatology Drugs Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2018 62

Figure 25: Dermatology Drugs Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2018 63

Figure 26: Dermatology Drugs Market, Global, Pipeline for Dermatology by Molecular Target Class, 2018 65

Figure 27: Dermatology Drugs Market, Global, Pipeline for Key Dermatology Indications by Molecular Target Class, 2018 66

Figure 28: Dermatology Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006–2018 67

Figure 29: Dermatology Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006–2018 68

Figure 30: Dermatology Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006–2018 69

Figure 31: Dermatology Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target Class and Stage of Development (%), 2006–2018 70

Figure 32: Dermatology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018 70

Figure 33: Dermatology Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006–2018 71

Figure 34: Dermatology Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006–2018 72

Figure 35: Dermatology Drugs Market, Global, Clinical Trial Duration by Molecular Target Class and Stage of Development (months), 2006–2018 73

Figure 36: Dermatology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018 73

Figure 37: Dermatology Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006–2018 74

Figure 38: Dermatology Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006–2018 75

Figure 39: Dermatology Drugs Market, Global, Clinical Trial Size by Molecular Target Class and Stage of Development (participants), 2006–2018 76

Figure 40: Dermatology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018 77

Figure 41: Dermatology Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006–2018 78

Figure 42: Dermatology Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006–2018 79

Figure 43: Dermatology Drugs Market, Global, Clinical Program Size by Molecular Target Class and Stage of Development (participants), 2006–2018 80

Figure 44: Dermatology Drugs Market, Global, Revenue Forecast for Risankizumab ($bn), 2019–2024 81

Figure 45: Dermatology Drugs Market, Global, Revenue Forecast for MOR106 ($m), 2023–2024 82

Figure 46: Dermatology Drugs Market, Global, Revenue Forecast for ANB-019 ($m), 2020–2024 83

Figure 47: Dermatology Drugs Market, Global, Revenue Forecast for Lebrikizumab ($m), 2021–2024 84

Figure 48: Dermatology Drugs Market, Global, Revenue Forecast for FMX-101 ($m), 2019–2024 85

Figure 49: Dermatology Drugs Market, Global, Market Size ($bn), 2017–2024 86

Figure 50: Dermatology Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024 88

Figure 51: Dermatology Drugs Market, Global, Annual Revenue Forecast for TNF-a inhibitors ($bn), 2017–2024 91

Figure 52: Dermatology Drugs Market, Global, Annual Revenue Forecast for IL-17 inhibitors ($bn), 2017–2024 92

Figure 53: Dermatology Drugs Market, Global, Annual Revenue Forecast for IL-23 inhibitors ($bn), 2017–2024 93

Figure 54: Dermatology Drugs Market, Global, Annual Revenue Forecast for IL-1, 4, 12, 13 and 33 inhibitors ($bn), 2017–2024 94

Figure 55: Dermatology Drugs Market, Global, Annual Revenue Forecast for PDE4 inhibitors ($bn), 2017–2024 95

Figure 56: Dermatology Drugs Market, Global, Annual Revenue Forecast for Glucocorticoids ($bn), 2017–2024 96

Figure 57: Dermatology Drugs Market, Global, Annual Revenue Forecast for JAK inhibitors ($bn), 2019–2024 97

Figure 58: Dermatology Drugs Market, Global, Company Analysis Matrix, 2017–2024 98

Figure 59: Dermatology Drugs Market, Global, Cluster by CAGR and Market Share, 2017–2024 99

Figure 60: Dermatology Drugs Market, Global, Market Share by Company (%), 2017–2024 105

Figure 61: Dermatology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024 107

Figure 62: Dermatology Drugs Market, Global, Revenues by Route of Acquisition, 2017–2024 108

Figure 63: Dermatology Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2017–2024 109

Figure 64: Dermatology Drugs Market, Global, Novartis, Annual Revenue Forecast ($bn), 2017–2024 110

Figure 65: Dermatology Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2017–2024 111

Figure 66: Dermatology Drugs Market, Global, Sanofi, Annual Revenue Forecast ($bn), 2017–2024 112

Figure 67: Dermatology Drugs Market, Global, Pfizer Annual Revenue Forecast ($bn), 2017–2024 114

Figure 68: Dermatology Drugs Market, Global, Eli Lilly Annual Revenue Forecast ($bn), 2017–2024 115

Figure 69: Dermatology Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Company Type, 2018 116

Figure 70: Dermatology Drugs Market, Global, Overall, High-Activity and Late-Stage Pipeline Developers by Level of Dermatology Specialization, 2018 117

Figure 71: Dermatology Drugs Market, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2017–2024 118

Figure 72: Dermatology Drugs Market, Global, Licensing Deals by Region, Deal Value and Year, 2006–2018 120

Figure 73: Dermatology Drugs Market, Global, Licensing Deals by Key Indication, 2006–2018 121

Figure 74: Dermatology Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018 122

Figure 75: Dermatology Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018 123

Figure 76: Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 1) 124

Figure 77: Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 2) 125

Figure 78: Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 3) 126

Figure 79: Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 4) 127

Figure 80: Dermatology Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018 128

Figure 81: Dermatology Drugs Market, Global, Co-development Deals by Indication, 2006–2018 129

Figure 82: Dermatology Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018 129

Figure 83: Dermatology Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018 130

Figure 84: Dermatology Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018 (part 1) 131

Figure 85: Dermatology Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018 (part 2) 132

Figure 86: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 1 140

Figure 87: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 2 141

Figure 88: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 3 142

Figure 89: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 4 143

Figure 90: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 5 144

Figure 91: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 6 145

Figure 92: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 7 146

Figure 93: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 8 147

Figure 94: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 9 148

Figure 95: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 10 149

Figure 96: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 11 150

Figure 97: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018 Part 12 151

Figure 98: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 13 152

Figure 99: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 14 153

Figure 100: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 15 154

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 20 7947 2745

Saved reports